CN102406859B - External traditional Chinese medicine composition for treating hepatitis B - Google Patents
External traditional Chinese medicine composition for treating hepatitis B Download PDFInfo
- Publication number
- CN102406859B CN102406859B CN201110394503.8A CN201110394503A CN102406859B CN 102406859 B CN102406859 B CN 102406859B CN 201110394503 A CN201110394503 A CN 201110394503A CN 102406859 B CN102406859 B CN 102406859B
- Authority
- CN
- China
- Prior art keywords
- parts
- grams
- chinese medicine
- traditional chinese
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an external traditional Chinese medicine composition for treating hepatitis B. The external traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 20-40 parts of white mustard seed, 7-13 parts of dragon's blood, 5-15 parts of croton, 20-35 parts of tabasheer, 15-35 parts of asafetida, 5-10 parts of wofberry bark, 0.5-1 part of musk and 140-160 parts of human milk. The traditional Chinese medicine composition embodies the characteristics of traditional Chinese medicine and western medicine treatment, and has the effects of unique, rapid, short and stable treatment effect, no recurrence and the like for chronic liver diseases. The external traditional Chinese medicine composition is a pure natural traditional Chinese medicine, is convenient for use, and is clinically verified to have rapid acting, definite treatment effect, high effective rate and good long-term effect. The traditional Chinese medicine composition has the advantages of low cost, good treatment effect and the like.
Description
Technical field
The present invention relates to a kind of external medicine composition for the treatment of hepatitis B.
Background technology
Viral hepatitis is the general designation of hepatic diseases, and hepatitis medically can be divided into first, second, third, fourth, penta, oneself, seven types of heptan.Viral hepatitis causes swelling of liver cell, is to spread in the world one of extensively very harmful infectious disease.Wherein hepatitis B be popular the most extensively, the most serious a kind of infectious hepatitis of harm.Hepatitis B, is the liver injury being caused by hepatitis B virus, primary disease extend over the entire globe.If the early symptom of hepatitis B and performance be as poor in loss of appetite, digestive function, enter abdominal distention after meal, there is no hunger sensation, detest and eat the greasy food vomiting that just can cause nausea of taking food, easily tired after activity.Method and the medicine for the treatment of hepatopathy are a lot, and aim of the present invention is to provide a kind of cost low, the externally applied ointment that therapeutic effect is good.
Summary of the invention
For above-mentioned prior art, the invention provides a kind of external medicine composition for the treatment of hepatitis B, its special effect, instant effect, short treating period, stable curative effect and difficult recurrence.
The present invention is achieved by the following technical solutions:
Treating an external medicine composition for hepatitis B, is to be made up of the crude drug of following weight portion: 20～40 parts of Semen Sinapis Albaes, 7～13 parts of Sanguis Draxonis, 5～15 parts of Fructus Crotonis, 20～35 parts of Concretio Silicea Bambusaes, 15～35 parts of Resina Ferulaes, 5～10 parts of Cortex Lycii, 0.5～1 part, Moschus, 140～160 parts of human milks.
Preferably, be to be made by the crude drug of following weight portion: 22 parts of Semen Sinapis Albaes, 12 parts of Sanguis Draxonis, 8 parts of Fructus Crotonis, 26 parts of Concretio Silicea Bambusaes, 30 parts of Resina Ferulaes, 10 parts of Cortex Lycii, 1 part, Moschus, 150 parts of human milks.
Preferably, be to be made by the crude drug of following weight portion: 37 parts of Semen Sinapis Albaes, 10 parts of Sanguis Draxonis, 10 parts of Fructus Crotonis, 30 parts of Concretio Silicea Bambusaes, 28 parts of Resina Ferulaes, 8 parts of Cortex Lycii, 0.8 part, Moschus, 140 parts of human milks.
Preferably, be to be made by the crude drug of following weight portion: 26 parts of Semen Sinapis Albaes, 11 parts of Sanguis Draxonis, 12 parts of Fructus Crotonis, 31 parts of Concretio Silicea Bambusaes, 32 parts of Resina Ferulaes, 5 parts of Cortex Lycii, 1 part, Moschus, 160 parts of human milks.
The preparation method of the external medicine composition of described treatment hepatitis B is: get the each crude drug except human milk, porphyrize powder is crossed 200 mesh sieves, mixes, and adds human milk, stirs into paste, to obtain final product.
In prescription of the present invention, the pharmacological action of each raw material and compatibility feature are summarized as follows:
Semen Sinapis Albae, Concretio Silicea Bambusae, Cortex Lycii: the bar expectorant of regulating the flow of vital energy, eliminating stagnation is conciliate, and removing heat from blood is except steaming.
Sanguis Draxonis, Resina Ferulae: the broken knot of blood circulation promoting and blood stasis dispelling ， Chu Disorder, passing corpse can go out.
Fructus Crotonis: the circulation of qi promoting intestinal stasis relieving ， Po mass in the abdomen hypochondriac lump.
Moschus: have one's ideas straightened out and ward off dirty removing toxic substances dissipating blood stasis.
All medicines share, and work the bar expectorant of regulating the flow of vital energy, the broken effect tying, reach treating the poisonous disease with poisonous drugs of removing toxic substances dissipating blood stasis, Chu Disorder.
The present invention is secret prescription handed down in the family from generation to generation, and according to China's traditional medical theory, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, cures mainly hepatitis B, and therapeutic modality is: external, plaster is affixed on to liver, and be a course for the treatment of January, pastes 7 days (paste continuously 7 days, all the other do not paste for 21 days) course for the treatment of.
Side effect: through there being clinical observations in 25 years of statistic record, do not find toxic and side effects.
Contraindication: anemia of pregnant woman, renal function injury and allergic constitution person forbidding.
Chinese medicine composition of the present invention has been given prominence to the characteristic of western medicines in treatment, and chronic hepatopathy has been played to special effect, fast, short, stable and do not recur texts.Great three positive turns virus and carries three months, adhere to that be consolidation half a year, and noinvasive is painless.Natural Chinese medicines, easy to use, through clinical verification, instant effect, determined curative effect, effective percentage is high, and long-term effect is good.Chinese medicine composition of the present invention has the advantages such as cost is low, good effect.
Detailed description of the invention
Below in conjunction with embodiment, clinical data and case, the present invention is further illustrated.
The external medicine composition of embodiment 1 preparation treatment hepatitis B
Formula is: 22 grams of Semen Sinapis Albaes, 12 grams of Sanguis Draxonis, 8 grams of Fructus Crotonis, 26 grams of Concretio Silicea Bambusaes, 30 grams of Resina Ferulaes, 10 grams of Cortex Lycii, 1 gram, Moschus, 150 grams of human milks (this is the consumption of potion, lower same).
Preparation method is: get the each crude drug except human milk, porphyrize powder sieves, and mixes, and adds human milk, stirs into paste, to obtain final product.
When treatment, external, is coated on the drug of topical application by Chinese medicine composition and sticks (consumption that coated weight is potion), is then affixed on liver.
The external medicine composition of embodiment 2 preparation treatment hepatitis B
Formula is: 37 grams of Semen Sinapis Albaes, 10 grams of Sanguis Draxonis, 10 grams of Fructus Crotonis, 30 grams of Concretio Silicea Bambusaes, 28 grams of Resina Ferulaes, 8 grams of Cortex Lycii, 0.8 gram, Moschus, 140 grams of human milks.
Preparation method is: get the each crude drug except human milk, porphyrize powder sieves, and mixes, and adds human milk, stirs into paste, to obtain final product.
The external medicine composition of embodiment 3 preparation treatment hepatitis B
Formula is: 26 grams of Semen Sinapis Albaes, 11 grams of Sanguis Draxonis, 12 grams of Fructus Crotonis, 31 grams of Concretio Silicea Bambusaes, 32 grams of Resina Ferulaes, 5 grams of Cortex Lycii, 1 gram, Moschus, 160 grams of human milks.
Preparation method is: get the each crude drug except human milk, porphyrize powder sieves, and mixes, and adds human milk, stirs into paste, to obtain final product.
The external medicine composition of embodiment 4 preparation treatment hepatitis B
Formula is: 20 grams of Semen Sinapis Albaes, 13 grams of Sanguis Draxonis, 5 grams of Fructus Crotonis, 35 grams of Concretio Silicea Bambusaes, 15 grams of Resina Ferulaes, 10 grams of Cortex Lycii, 1 gram, Moschus, 150 grams of human milks.
Preparation method is: get the each crude drug except human milk, porphyrize powder sieves, and mixes, and adds human milk, stirs into paste, to obtain final product.
The external medicine composition of embodiment 5 preparation treatment hepatitis B
Formula is: 40 grams of Semen Sinapis Albaes, 7 grams of Sanguis Draxonis, 15 grams of Fructus Crotonis, 20 grams of Concretio Silicea Bambusaes, 35 grams of Resina Ferulaes, 5 grams of Cortex Lycii, 0.5 gram, Moschus, 160 grams of human milks.
Preparation method is: get the each crude drug except human milk, porphyrize powder sieves, and mixes, and adds human milk, stirs into paste, to obtain final product.
Clinical data:
Patient's data: from April, 1986, there are outpatient 4689 people of complete data, 11～57 years old age, the course of disease is the longest 18 years, all suffers from hepatitis B (most hepatitis B great three positive for chronic hepatitis of active stage), wherein, man 3908 people, 45 years old mean age, female 781 people, 40 years old mean age.
Diagnosis basis: ten of liver functions, six of hepatitis B, ultrasound diagnosis, oral account general lassitude, weak, loss of appetite, feels sick and detest oil, yellow complexion, yellow urine.
Therapeutic Method: 4689 routine patients are divided into treatment group and matched group at random, wherein, treatment group 3201 examples, matched group 1488 examples, the drug external that treatment group patient uses embodiment 3 to prepare, once a day, monthly pasting seven days is a course for the treatment of, treats three courses for the treatment of.The silybin of the oral routine dose of matched group, and inject the interferon of routine dose.
The standard of curative effect evaluation:
Cure: liver histological checks Non Apparent Abnormality, and great three positive transfers virus to and carries.
Invalid: the state of an illness is without significant change.
Therapeutic outcome: treatment group 3201 examples, cure 2732 examples, invalid 469 examples, cure rate 85.3%.Contrast 1488 examples, cure 737 examples, invalid 751 examples, cure rate 49.5%.Visible, traditional Chinese medicine composition for treating successful of the present invention is better than silybin.
Case:
Case 1 tunnel, man 39 years old, hepatitis more than 10 years, ten index checkings of liver function, great three positive, transaminase are high, and uncomfortable liver area is weak, insomnia, loss of appetite, takes the medicine of multiple treatment hepatopathy, and once Multiple Hospitalization treatment is showed no and is clearly better, use plaster of the present invention (prepared by embodiment 3) treatment to continue to check after 3 courses for the treatment of, turned virus and carried, for after treatment again continual cure three courses for the treatment of, 7 years afterwards pay a return visit without recurrence.
Case 2 cloth, female 25 years old, hepatitis B, liver function index checks great three positive, once transfusion, injection of interferon, SM had no improvement 3 years more.Use after three courses for the treatment of of ointment of the present invention (prepared by embodiment 3), through liver function test, turned virus and carried, liver histological checks Non Apparent Abnormality.For consolidating curative effect, 3 courses for the treatment of of continual cure again, within 2 years, pay a return visit afterwards without recurrence.
Case 3 fields, man 17 years old, hepatitis B great three positive, the weak anorexia of yellowish complexion, Chinese medicine and western medicine, interferon, SM had no improvement 2 years more, used after plaster of the present invention (prepared by embodiment 3), and 3 checks course for the treatment of have turned virus and carried, continued treatment does to consolidate three courses for the treatment of again, after 3 years, has no recurrence.
Case 4 journeys, 45 years old hepatitis B great three positive of man, liver's dull pain, inappetence, weak once hospitalization, takes the medicine of multiple Chinese medicine and western medicine treating the liver nourishing the liver and does not feel any better, use three courses for the treatment of of plaster of the present invention (prepared by embodiment 1), check has turned virus and has carried.There is no continual cure, after 6 years, follow up a case by regular visits to without recurrence.
5 Weis of case, man 35 years old, hepatitis B great three positive, within 15 years, be not interrupted the medicine of taking treatment hepatitis B, have no and be clearly better, through using plaster of the present invention (prepared by embodiment 1) treatment, continue after three courses for the treatment of check and turned virus and carry, continue again to have used three courses for the treatment of to consolidate curative effect, after 3 years, follow up a case by regular visits to and have no recurrence.
Case 6 single certain, man 11 years old, hepatitis B great three positive, the Chinese and western drugs that continues to take treatment hepatitis B is not controlled the small three positive state of an illness for 9 months, makes progress as great three positive.Since having used plaster of the present invention (prepared by embodiment 2), after three courses for the treatment of, just transfer virus to and carry, adhere to having used and do half a year to consolidate, after 3 years, follow up a case by regular visits to without recurrence.
Case 7 Cui, man 26 years old, hepatitis B great three positive, transaminase is high, clinical manifestation heating, inappetence, complexion eyeball xanthochromia, the symptom such as lower limb are aching and limp, once used the liver protecting and ALT lowering jaundice eliminating medicine, there is no effect.3 courses for the treatment of after using plaster of the present invention (prepared by embodiment 2), have turned virus and have carried, and three courses for the treatment of of SM, do not follow up a case by regular visits to recurrence after 2 years.
Claims (1)
1. an external medicine composition for the treatment of hepatitis B, is characterized in that, is made up of following crude drug: 26 grams of Semen Sinapis Albaes, 11 grams of Sanguis Draxonis, 12 grams of Fructus Crotonis, 31 grams of Concretio Silicea Bambusaes, 32 grams of Resina Ferulaes, 5 grams of Cortex Lycii, 1 gram, Moschus, 160 grams of human milks; Preparation method is: get the each crude drug except human milk, porphyrize powder is crossed 200 mesh sieves, mixes, and adds human milk, stirs into paste, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110394503.8A CN102406859B (en) | 2011-12-01 | 2011-12-01 | External traditional Chinese medicine composition for treating hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110394503.8A CN102406859B (en) | 2011-12-01 | 2011-12-01 | External traditional Chinese medicine composition for treating hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102406859A CN102406859A (en) | 2012-04-11 |
| CN102406859B true CN102406859B (en) | 2014-07-23 |
Family
ID=45909394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110394503.8A Expired - Fee Related CN102406859B (en) | 2011-12-01 | 2011-12-01 | External traditional Chinese medicine composition for treating hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102406859B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1197667A (en) * | 1998-03-11 | 1998-11-04 | 张学勤 | Externally used medicine for hepatitis B |
| CN1223127A (en) * | 1998-01-15 | 1999-07-21 | 韩钰 | Tongguanshugan ointment and preparation process thereof |
-
2011
- 2011-12-01 CN CN201110394503.8A patent/CN102406859B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223127A (en) * | 1998-01-15 | 1999-07-21 | 韩钰 | Tongguanshugan ointment and preparation process thereof |
| CN1197667A (en) * | 1998-03-11 | 1998-11-04 | 张学勤 | Externally used medicine for hepatitis B |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102406859A (en) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058784A (en) | Medicinal composition for treating pulmonary heart disease and application thereof | |
| CN101897882B (en) | Medicament for treating and breast lobular hyperplasia and cyst | |
| CN103948782B (en) | Pharmaceutical composition for treating hyperplasia of mammary glands due to stagnation of liver qi as well as preparation method and application of pharmaceutical composition | |
| CN104147462A (en) | Medicine for treating psoriasis vulgaris | |
| CN100381155C (en) | Medicine for treating mammary glands hyperplasia | |
| CN102302559B (en) | Medicament for treating respiratory system diseases and application thereof | |
| CN102579999A (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN102824576B (en) | Traditional Chinese medicinal composition for treating psoriasis and preparation method thereof | |
| CN101549138B (en) | Acne treating Chinese medicine preparation and method of producing the same | |
| CN102406859B (en) | External traditional Chinese medicine composition for treating hepatitis B | |
| CN103127287A (en) | Traditional Chinese medicine composition for curing eczema | |
| CN100566741C (en) | A kind of antipsoriatics thing | |
| CN105055926A (en) | Pharmaceutical composition for treating infantile hand-foot-mouth disease | |
| CN104096170B (en) | External-use ultra-fine powder traditional Chinese medicine for weight loss and preparation method thereof | |
| CN102552495A (en) | Traditional Chinese medicine composition for preventing poultry syndrome of pathogen invading lung-defense phase | |
| CN107714995A (en) | A kind of Chinese medicine for treating hemorrhoid | |
| CN103157072B (en) | Chinese medicinal composition for treating cervical spondylosis | |
| CN102258589B (en) | Deer blood medicinal wine for treating rheumatoid arthritis | |
| CN101912584A (en) | Medicine for treating melancholia and preparation method thereof | |
| CN101185697B (en) | Ointment medicine for treating anal fissure | |
| CN101361882B (en) | Chinese medicine formulation for treating rheumatic osteoarthropathy | |
| CN105617132A (en) | Application of traditional Chinese medicine composition in preparing scapulohumeral periarthritis or myotenositis treatment drugs | |
| CN1823890B (en) | Formula of oral Chinese medicine used for treating virus myocarditis | |
| CN103505697A (en) | Medicine used for treating orthopaedic diseases, and preparation method thereof | |
| CN102151319B (en) | Hepatitis treatment medicament for oral administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140723 Termination date: 20151201 |
|
| EXPY | Termination of patent right or utility model |